X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.
Lead Product(s): COVI-VAC
Therapeutic Area: Infections and Infectious Diseases Product Name: COVI-VAC
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Codagenix
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
The deal aims at conducting a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.
Lead Product(s): CodaVax-COVID
Therapeutic Area: Infections and Infectious Diseases Product Name: CodaVax-COVID
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Codagenix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 28, 2020
Details:
For this human challenge study model, the common coronavirus strains such as OC43 and 229E, will provide an effective tool to obtain fast proof-of-concept data against this family of viruses.
Lead Product(s): OC43 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
